medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2015, Number 04

<< Back Next >>

Ginecol Obstet Mex 2015; 83 (04)

Clinical implementation of non-invasive prenatal study for detecting aneuploidies by fetal DNA based on single nucleotide polymorphisms: two years in Mexico

Sánchez-Usabiaga RA, Aguinaga-Ríos M, Batista-Espinoza A, Hurtado-Amador R, Romero-Tovar S

Language: Spanish
References: 45
Page: 220-231
PDF size: 403.66 Kb.


ABSTRACT

Background: Recent data have shown that non invasive prenatal test (NIPT) for the detection of fetal aneuploidies (chromosomes 13, 18, 21, X, Y, and triploidy) by cell free fetal DNA in maternal blood (cfDNA) is a clinical reality, with detection rates> 99% and false positive rates of 0.1%. Results that exceed the first trimester screening.
Objective: To describe our experience of 2 years integrating NIPT by cfADN in its variant of single nucleotide polymorphism (SNPs) as a screening method for the detection of common aneuploidies, since nine weeks of gestation.
Patients and methods: Observational prospective study from March 2013 to February 2015. Women with a singleton pregnancy were offered conventional prenatal screening fetal aneuploidy and or new alternative NIPT-SNPs.
Results: 270 women were included,the mean maternal age was 35.3 years with a mean gestational age of 11.85 weeks. The result was obtained in 98.5%, with an average report time of 7.5 working days. Blood collection was repeated in fifteen patients, obtaining the result in eleven. The NIPT tested positive for ten cases, 8 for trisomy 21, one for trisomy 18 and one trisomy 13.
Conclusions: We describe our first two years of integrating NIPT-SNPs to obstetric private practice, that is an alternative screening with the potential to be incorporated into theexisting algorithms in prenatal care, from the ninth week of gestation. We expect this information will motivate a debate on the issue of prenatal screening and get to improve obstetric care and genetic counseling in Mexico.


REFERENCES

  1. Chitty LS, Bianchi DW. Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn 2013;33:511-3.

  2. Pergament E, Cuckle H, Zimmermann B, et al. Singlenucleotide polymorphism-based noninvasive prenatal testing in a high-risk and low-risk cohort. ObstetGynecol 2014;124: 210-8.

  3. Nicolaides KH, Syngelaki AQil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33:575-9.

  4. Samango-Sprouse C, Banjevic M, Ryan A, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. PrenatDiagn 2013;33:643- 9.

  5. Nicolaides KH, Syngelaki A, Gil MD, Quezada MS, Zinevich Y. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal DiagnTher 2014;35: 212-7.

  6. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genomewide fetal aneuploidy detection by maternal plasma DNA sequencing.ObstetGynecol 2012;119:890-901.

  7. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14: 296–305.

  8. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.

  9. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J ObstetGynecol 2012;206: 322.e1-5.

  10. Ashoor G, Syngelaki A, Wang E, et al. Trisomy 13 detection in the first trimester of pregnancy using a chromosomeselective cell free DNA analysis method. Ultrasound Obstet Gynecol 2013; 41:21-5.

  11. Norton ME, Brar H, Weiss J, et al. Noninvasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J ObstetGynecol 2012;207: 137.e1-8.

  12. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J ObstetGynecol 2012; 206: 319. e1-9.

  13. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3-9.

  14. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370: 799-808.

  15. Benn P, Borell A, Chiu R, et al. Position statement from the aneuploidy screening committee on behalf of the Board of the International Society for Prenatal Diagnosis. PrenatDiagn 2013;33:622-9.

  16. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013; 15: 395-8.

  17. American College of Obstetricians and Gynecologists. Noninvasive prenatal testing for fetal aneuploidy.Committee opinion no. 545.ObstetGynecol 2012; 120: 1532-4.

  18. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive Prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J ObstetGynecol2012; 207: 374.e1–6.

  19. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. PrenatDiagn2011; 31: 7–15.

  20. Zimmermann B, Hill M, Gemelos G, Demko Z, Banjevic M, Baner J, Ryan A, Sigurjonsson S, Chopra N, Dodd M, Levy B, Rabinowitz M. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. PrenatDiagn 2012; 32: 1233-41.

  21. Sánchez-Usabiaga RA, Batista-Espinoza A, Romero-Tovar. Estudio prenatal no invasivo para la detección de aneuploidías mediante ADN fetal libre en sangre materna: descripción de tres metodologías. Reproducción (México) 2013; 6: 83-89.

  22. Verweij EJ, Jacobsson B, van Scheltema PA, de Boer MA, Hoffer MJ, Hollemon D, Westgren M, Song K, Oepkes D. European non-invasive trisomy evaluation (EU-NITE) study: a multicenter prospective cohort study for non-invasive fetal trisomy 21 testing. PrenatDiagn 2013;33:996-1001.

  23. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au

  24. Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validation study. BMJ 2011; 342: c7401.

  25. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP, on behalf of the MatErnalBLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA). Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing.ObstetGynecol 2012; 119: 890–901.

  26. Stumm M, Entezami M, Haug K, Blank C, Wüstemann M, Schulze B, Raabe-Meyer G, Hempel M, Schelling M, Ostermayer E, Langer-Freitag S, Burkhardt T, Zimmermann R, Schleicher T, Weil B, Schöck U, Smerdka P, Grömminger S, Kumar Y, Hofmann W. Diagnostic accuracy of random massively parallel sequencing for non-invasive prenatal detection of common autosomal aneuploidies: a collaborative study in Europe. PrenatDiagn 2014;34: 185-91.

  27. Lau TK, Chan MK, Lo PS, et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test-early experience. J Matern Fetal Neonatal Med 2012;25: 1856-9.

  28. Gil MM, Quezada MS, Bregant B, Ferraro M, NicolaidesKH. Implementation of maternal blood cell free DNA testing in early screening for aneuploidies. Ultrasound ObstetGynecol 2013;42:34-40.

  29. Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn2013;33:580-3.

  30. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, Oliver K, Rava RP, Sehnert AJ; CARE Study Group. DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N Engl J Med 2014; 370: 799-808.

  31. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. PrenatDiagn 2013; 33: 569–574.

  32. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in highrisk women based on a US population. J Matern Fetal Neonatal Med 2013; 26: 1180-1185.

  33. Eric Wang, Annette Batey, Craig Struble, Thomas Musci, Ken Song and Arnold Oliphant Article first published online: 9 MAY 2013 | DOI: 10.1002/pd.4119 Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma (pages 662–666).

  34. Bernhard Zimmermann, Matthew Hill, George Gemelos, Zachary Demko, Milena Banjevic, Johan Baner, Allison Ryan, StyrmirSigurjonsson, Nikhil Chopra, Michael Dodd, Brynn Levy and Matthew Rabinowitz. Non invasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci Prenatal Diagnosis 2012, 32, 1–9

  35. Dar P, Curnow KJ, Gross SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism— based noninvasive prenatal aneuploidy testing. Am J ObstetGynecol 2014;211:527.e1-17.

  36. Garfield SS, Amstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Managed Care Medicine 2012;15:34-41.

  37. Manegold-Brauer G, Kang Bellin A, Hahn S, De Geyter C, Buechel J, Hoesli I, Lapaire O. A new era in prenatal care: non-invasive prenatal testing in Switzerland. Swiss Med Wkly 2014; 144: w13915.

  38. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies.PrenatDiagn 2013;33:667-74.

  39. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cellfree DNA in maternal plasma. PrenatDiagn 2013; 33: 662-6.

  40. Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal DiagnTher 2013; 33: 215-23.

  41. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound ObstetGynecol 2013; 41: 26-32.

  42. Brownstein Z, Friedman LM, Shahin H, Oron-Karni V, Kol N, Rayyan AA, Parzefall T, Lev D, Shalev S, Frydman M, et al: Targeted genomic capture and massively parallel sequencing to identify genes for hereditary hearing loss in middle eastern families. Genome Biol 2011, 12(9):R89.

  43. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, et al: Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011, 3(65):65ra64.

  44. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013;42:41-50.

  45. Non-invasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545.American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120: 1532–1534.




2020     |     www.medigraphic.com